• +1 700 888 1234

  • Effingerstrasse 40 3008 Bern Switzerland

FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer

Some positive news last week when the U.S. Food and Drug Administration (FDA) approved alectinib as an adjuvant treatment for […]

Five new members join the Lung Cancer Europe (LuCE) network

We’re delighted to welcome five new member organisations to our growing Lung Cancer Europe (LuCE) network. These organisations and their […]

BMS Press Release is out now

Bristol Myers Squibb has released a new Press Release announcing that the European Medicines Agency (EMA) has validated the marketing authorization application for repotrectinib. Repotrectinib […]

Press Release: High risk of financial vulnerability after diagnosis: The majority of people impacted by lung cancer experience higher costs and reduction in income

Financial impact of lung cancer: A European perspective High risk of financial vulnerability after diagnosis:  The majority of people impacted […]

LuCE attending the European Medicines Agency (EMA) in Amsterdam

November 14th – 15th in Amsterdam We are delighted to announce that Lung Cancer Europe (LuCE) is participating in a two-day meeting […]

Lung Cancer Awareness Month

November is Lung Cancer Awareness Month, a perfect time to be proactive and be aware.